Crispr Therapeutics AG (1CG)

40.0000
0.0000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    41.0000/41.2000
  • Day's Range:
    39.4000 - 40.0000
  • Type:Equity
  • Market:Germany
  • ISIN:CH0334081137
  • WKN:A2AT0Z

1CG Overview

Prev. Close
39.6
Day's Range
39.4-40
Revenue
-
Open
39.4
52 wk Range
0-0
EPS
-
Volume
0
Market Cap
4.91B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
-
P/E Ratio
10.29
Beta
-
1-Year Change
0%
Shares Outstanding
77,457,081
Next Earnings Date
-
What is your sentiment on Crispr Therapeutics?
or
Vote to see community's results!

Crispr Therapeutics AG Analysis

Crispr Therapeutics AG Company Profile

Crispr Therapeutics AG Company Profile

Employees
473

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company’s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary
  • Time to load up
    0
    • Nice price
      0
      • The earning date posted here is wrong. Its 2/16/22. So miss leading
        0
        • wow... it's bucking the trend
          0
          • another cathy wood investment ¡ Good luck ...enjoy the elevator
            4
            • CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignanciesZUG, Switzerland and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-fda-regenerative-medicine-advanced
              0
              • Amazing how fast this went from breakthrough life changing technology to garbage in about a month
                1
                • One paragraph of good news and this goes back to 160 in a day after the sheep pile in. Not just this ticker but any of them.
                  0
                  • Added 1100 shares
                    2
                    • now u must be regretting
                      0
                    • nope I'm long!
                      0
                  • keep tanking this stock what a hopeless
                    6